© PR Newswire
12.01.2026
NUTX
LISTED
NASDAQ
NUTEX HEALTH RE-OPENS BAYOU CITY ER & HOSPITAL IN HOUSTON
News Preview
HOUSTON, Jan. 12, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced the reopening...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
OCGN
LISTED
NASDAQ
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
News Preview
MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journa...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
ZYME
LISTED
NYSE
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
News Preview
VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intend...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
12.01.2026
TDOC
LISTED
NYSE
Teladoc Health Launches Enhanced 24/7 Care Service
News Preview
New capabilities enable Teladoc Health’s care teams to address a broader spectrum of health needs, delivering more value in virtual urgent care visits...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
12.01.2026
BDSX
LISTED
NASDAQ
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
News Preview
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%;...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
2359
LISTED
HKSE
WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025
News Preview
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data, with revenue from Continuing Operations growing by...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
FWBI
LISTED
NASDAQ
GridAI and the Financial Mechanics of Grid Intelligence
News Preview
BOCA RATON, FL / ACCESS Newswire / January 12, 2026 / Grid intelligence only matters if it changes cost structures, creates new revenue streams, or both. Otherwise, it's just another layer of software observing problems it can't influence. The reason grid orchestration, and the companies providing it, have moved from theoretical discussion to an in...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
CTKB
LISTED
NASDAQ
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
News Preview
Company to present at the 44th Annual JP Morgan Healthcare Conference Company to present at the 44th Annual JP Morgan Healthcare Conference...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC PINK:MDCE) 2026 Annual Shareholder Update and Strategic Roadmap
News Preview
MESA, AZ / ACCESS Newswire / January 12, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), a technology-focused company developing AI-driven consumer, wellness, and medical applications, today provided its 2026 annual shareholder update outlining its short-term, near-term, and long-term strategic g...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
TIVC
LISTED
NASDAQ
Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity
News Preview
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly owned contract development manufacturing organization (CDMO), Velocity BioworksCompany's next step is to initiate production under current Good Manufacturing Practice (cGMP), a critical milest...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
CASI
LISTED
NASDAQ
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
News Preview
Additional proof of concept data consistent and strengthen data set shared at ASH 2025Management to host meetings at JP Morgan 44th Annual Healthcare Conference 2026 SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
JAGX
LISTED
NASDAQ
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
News Preview
$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)Up to additional $20M in milestone and other future paymentsFuture Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1Jaguar continues to be the manufacturer of Mytesi and Canalevia-CA1Meaningful non-dilutive capital en...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
12.01.2026
IGC
LISTED
XASE
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
News Preview
- Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities - POTOMAC, MD / ACCESS Newswire / January 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to dev...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
CLPT
LISTED
NASDAQ
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
News Preview
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced p...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
AIMD
LISTED
NASDAQ
Water Tower Research Highlights Ainos SmellTech's Rising Commercial Momentum in Scalable AI Infrastructure Platform Shift
News Preview
AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue modelNew Trusval agreement commits to minimum 600-unit deployment, positioning AI Nose into front-end semiconductor manufacturing HOUSTON, TEXAS / ACCESS Newswire / January 12, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIM...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
VSEE
LISTED
NASDAQ
VSee Launches AI-Driven Rural Health Transformation Platform, Targeting Millions in Recaptured Revenue Per Hospital
News Preview
VSee's Rapidly Configurable AI Telehealth Platform Addresses Rural Hospital Access and Financial Sustainability SAN JOSE, CALIFORNIA / ACCESS Newswire / January 12, 2026 / VSee Health, Inc. (Nasdaq:VSEE) today announced the launch of its AI‑enhanced Rural Health Transformation Solution, a modular platform designed to help rural hospitals expand spe...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
AYTU
LISTED
NASDAQ
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
News Preview
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Da...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
FWBI
LISTED
NASDAQ
GridAI: The Grid Is the New Battleground for AI Economics
News Preview
BOCA RATON, FL / ACCESS Newswire / January 12, 2026 / For years, investors were trained to believe the bottleneck in artificial intelligence would be chips. Then it was talent. Then it was data. Each time, the market adjusted, capital flowed, and new winners emerged. What has changed quietly, but decisively, is where that constraint now lives.Elect...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
QGEN
LISTED
NYSE
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
News Preview
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and automation system innovations to support its goal for $2 billion of combined annual pillar sales in 2028.
Following strong operational execution in 20...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
WGRX
LISTED
NASDAQ
Wellgistics Health Adds Quantum Key Encryption to PharmacyChain(TM) AI-Enabled Blockchain Smart Contract Partnership with DataVault AI
News Preview
Feasibility assessment completed, PharmacyChain™ to leverage Datavault AI's edge network and quantum key encryption to improve data driven outcomes in $634 billion prescription drug marketQuantum key encryption fortities pharmacies from quantum's pending encryption-busting impact on traditional encryption methods TAMPA, FLORIDA / ACCESS Newsw...
Themefolio
Profiler
Peergroup
© Newsfile
12.01.2026
COPN
LISTED
SIX
Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms
News Preview
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma. Financial Highlights: High quality growth: €104 million revenue...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
MRNA
LISTED
NASDAQ
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q25 Earnings CallIncreases 2025 projected year-end cash balance to approximately $8.1 billion (unaudited)Reiterates plan to deliver up to 10% revenue grow...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
News Preview
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the "Agreement") with Nanjing Hanxin Pharmaceutica...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
FAGR
LISTED
EURONEXT
Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America
News Preview
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
IDIA
LISTED
SIX
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
News Preview
Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 10:30 am PST / 7:30 pm CET. The conference will take place at the Westin St. Francis hotel in San Francisco, USA....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
NYXH
LISTED
NASDAQ
Publication relating to transparency notification
News Preview
REGULATED INFORMATION...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
News Preview
Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
IDIA
LISTED
SIX
Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
News Preview
Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, an oral substrate reduction therapy, in adults with Fabry disease. The data, published in Nature Communications, titled “Lucerastat, an oral therapy for...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
NTRA
LISTED
NASDAQ
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following:
Total revenues of approximately $660 million in the fourth quarter of 2025 compared to $476 million in the fourth quar...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.01.2026
CLBX
LISTED
AIMX
CelLBxHealth PLC Announces Board Changes
News Preview
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 December 2025, that the following have been appointed to the...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
TEM
LISTED
NASDAQ
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmith...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
ZYME
LISTED
NYSE
Zymeworks Outlines Strategic Priorities and Outlook for 2026
News Preview
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significan...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
ESPR
LISTED
NASDAQ
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
News Preview
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
TEVA
LISTED
TLV
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
News Preview
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
GH
LISTED
NASDAQ
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025.
Fourth quarter 2025 preliminary unaudited financial results
For the three-month period ended December 31, 2025, as compared to the same period of 2024:
Total revenue...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
VRTX
LISTED
NASDAQ
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT.
“2025 was a year of strong commercial execution...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
ALNY
LISTED
NASDAQ
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with dis...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
TEM
LISTED
NASDAQ
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.
Full Year 2025 Select, Preliminary, Unaudited Financial Results
Revenue of ~$1.27 billion, representing ~83% growth y...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
VCYT
LISTED
NASDAQ
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Preliminary Unaudited Financial Results
For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
RPRX
LISTED
NASDAQ
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
News Preview
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-'408. IL-15...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
DAWN
LISTED
NASDAQ
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
News Preview
Day One today announced the release of preliminary 2025 OJEMDA™ net product revenue and provides 2026 net product revenue guidance...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
BEAM
LISTED
NASDAQ
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
News Preview
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
KURA
LISTED
NASDAQ
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
News Preview
– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML –...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
TEVA
LISTED
TLV
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
News Preview
PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-’408. IL-1...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
EXEL
LISTED
NASDAQ
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozanti...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
CERS
LISTED
NASDAQ
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
News Preview
Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026.
“2025 was a remarkable year for Cerus, as patient access to INTERCEPT treated blood components increased meaningfully around the world,” said Wil...
Themefolio
Profiler
Peergroup
© PR Newswire
11.01.2026
RGNX
LISTED
NASDAQ
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
News Preview
New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed by planned BLA filing, mid-yearExpecting FDA PDUFA decision and multiple pivotal top-line data readouts in 2026 to support potential...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
MBX
LISTED
NASDAQ
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
News Preview
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
CSTL
LISTED
NASDAQ
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
News Preview
Castle today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
MOLN
LISTED
SIX
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
News Preview
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update on...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
XGN
LISTED
NASDAQ
Exagen Inc. Announces Select Preliminary 2025 Financial Results
News Preview
Exagen Inc. announces select preliminary unaudited financial results for the fourth quarter and full year 2025, in line with prior guidance....
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2026
STOK
LISTED
NASDAQ
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the...
Themefolio
Profiler
Peergroup
© PR Newswire
11.01.2026
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026. The company will review these updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference...
Themefolio
Profiler
Peergroup
© PR Newswire
11.01.2026
TXG
LISTED
NASDAQ
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
News Preview
PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
KRYS
LISTED
NASDAQ
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
RXST
LISTED
NASDAQ
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
News Preview
ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In add...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
BNTC
LISTED
NASDAQ
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
News Preview
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2026
BBNX
LISTED
NASDAQ
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed...
Themefolio
Profiler
Peergroup
© PR Newswire
10.01.2026
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
News Preview
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable responses were also seen in patients with liver metastases, who often face poorer outcomes with this diseaseRARITAN, N.J., Jan. 10, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announc...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2026
PFE
LISTED
NYSE
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
